Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy-induced nausea and vomiting, alter cytochrome P450 activity.
Heron Therapeutics, Inc. announced that the FDA has approved Aponvie (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults. Aponvie is the first and only IV formulation of aprepitant for PONV prevention
Merck announced that the FDA has approved a supplemental New Drug Application (sNDA) for Emend (aprepitant) capsules, a substance P/neurokinin...
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12. Aprepitant 125mg/80 mg is given as part of combination therapy (see section 4.2).